Silodosin
Approved · EMAAlso known as Rapaflo, Silodosina.
Recent clinical, regulatory, research and industry developments relating to this drug.
Approval: Silodosin Recordati (EMA)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult men.
Evidence ↗Indication: Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
Evidence ↗Indication: Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH)
Evidence ↗Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes1
Journals, researchers & institutions
- The Journal of urology1
- Urology1
- Gittelman MC2
- Hill LA2
- Hoel G2
- Marks LS2
- Volinn W2
- University of California at Los Angeles and Urological Sciences Research Foundation1
- Urological Sciences Research Foundation1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.